Commercial-stage biotech companies
27 listed drug developers whose lead program is marketed, largest first, with the next catalyst each has disclosed.
| Company | Ticker | Lead program | Indication | Next catalyst |
|---|---|---|---|---|
| Johnson & Johnson | JNJ | DARZALEX (daratumumab) | Multiple myeloma | — |
| AbbVie Inc. | ABBV | Skyrizi | Multiple immunology indications (plaque psoriasis, Crohn's disease, ulcerative colitis, psoriatic arthritis) | Q4 2026 — CD subcutaneous induction regulatory review (EU application submitted Aug 2026, US approval Oct 2026) |
| Abbott Laboratories | ABT | — | — | — |
| Stryker Corp | SYK | Versius Plus surgical robot (CMR Surgical partnership) | Surgical procedures (general robotics platform) | — |
| Boston Scientific Corporation | BSX | — | — | Q1 2027 — Acquisition closing (pending FTC review) |
| Baxter International Inc. | BAX | — | — | — |
| Haemonetics Corporation | HAE | — | — | 2027 — Complete rollout of devices to all CSL U.S. plasma collection centers |
| Organon & Co. | OGN | Miudella | contraception (hormone-free copper IUD) | Q4 2026 — U.S. commercial launch |
| Indivior PLC | SUPN | — | — | H1 2027 — Transaction close and regulatory approval of marketing authorization transfer |
| AtriCure, Inc. | ATRC | BoxX-NoAF (Box Lesion and Left Atrial Appendage Exclusion Procedure) | Prevention of New Onset Atrial Fibrillation (Post-operative AF and Clinical AF) | Q4 2026 — Commercial launch |
| Alvotech | ALVO | SIMLANDI (adalimumab-ryvk) | Humira (adalimumab) biosimilar; autoimmune disease | — |
| Innoviva, Inc. | INVA | — | — | — |
| Harrow, Inc. | HROW | VEVYE (cyclosporine ophthalmic solution) 0.1% and branded ophthalmic portfolio | dry eye disease (VEVYE); portfolio spans ocular anesthesia, retina, post-operative inflammation and others | 2027 — Commercial launch (FDA-approved EYLEA biosimilar) |
| Artivion, Inc. | AORT | NEXUS family of products (aortic arch stent graft systems) | Aortic disease / aortic arch reconstruction | — |
| Collegium Pharmaceutical, Inc | COLL | — | — | — |
| OmniAb, Inc. | OABI | — | — | — |
| Sight Sciences, Inc. | SGHT | OMNI Surgical System | Glaucoma | — |
| AVITA Medical, Inc. | RCEL | RECELL | thermal burn wounds and full-thickness skin defects | 2026 — CMS final rules for 2027 Medicare Physician Fee Schedule expected |
| MIMEDX Group Inc. | MDXG | — | — | — |
| Emergent BioSolutions Inc. | EBS | — | — | — |
| Amarin Corporation plc | AMRN | VASCEPA (icosapent ethyl) | Cardiovascular risk reduction in high-risk statin-treated patients with elevated triglycerides | — |
| Neuronetics, Inc. | STIM | NeuroStar Advanced Therapy System | Major Depressive Disorder (MDD), Obsessive-Compulsive Disorder (OCD), Anxious Depression | — |
| Journey Medical Corp | DERM | Emrosi (minocycline modified-release capsules 40 mg) | Inflammatory lesions of rosacea in adults | — |
| LENZ Therapeutics, Inc. | LENZ | VIZZ (aceclidine ophthalmic solution) 1.44% | Presbyopia | — |
| Outlook Therapeutics, Inc. | OTLK | LYTENAVA (bevacizumab-vikg) | wet age-related macular degeneration | Q4 2026 — US commercial launch |
| Citius Oncology, Inc. | CTOR | LYMPHIR (denileukin diftitox-cdxl) | persistent or recurrent cutaneous T-cell lymphoma | December 2026 — Citius Oncology expects to report complete fiscal Q4 and full year 2026 results in December 2026 with Form 10-K filing. |
| Aytu Biopharma, Inc | AYTU | EXXUA (gepirone) extended-release | major depressive disorder in adults | — |
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.